Actualités Callisto Pharmaceuticals, - KAL | Actions American Stock Exchange

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Callisto Pharmaceuticals Inc - Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to...

Callisto Pharmaceuticals Inc - Quarterly Report (10-Q)

QuickLinks -- Click here to rapidly navigate through this document UNITED STATES OF AMERICA SECURITIES AND EXCHANGE COMMISSION WASHINGTON...

Callisto Pharmaceuticals Inc - Amended Statement of Ownership (SC 13G/A)

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _________________ SCHEDULE 13G INFORMATION STATEMENT PURSUANT TO RULES 13D-1 AND...

Callisto Pharmaceuticals Inc - Notice of Effectiveness (EFFECT)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESS Effective Date: April 23, 2008 Form: S-3...

Callisto Pharmaceuticals Inc - Securities Registration Statement (simplified form) (S-3)

As filed with the Securities and Exchange Commission on April 16, 2008 Registration No. 333- &nb...

Callisto Pharmaceuticals Inc - Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to...

Callisto Pharmaceuticals, Inc. Receives Notice of Delisting From Amex - Subject to Appeal -

Callisto Pharmaceuticals, Inc. (AMEX: KAL), announced today that on April 7, 2008, it received notice from the American Stock...

Callisto Pharmaceuticals Inc - Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K ...

Callisto Pharmaceuticals Inc - Annual Report (10-K)

QuickLinks -- Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549...

Callisto Pharmaceuticals Inc - Statement of Ownership (SC 13G)

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _________________ SCHEDULE 13G INFORMATION STATEMENT PURSUANT TO RULES 13D-1 AND...

Callisto Pharmaceuticals Inc - Prospectus filed pursuant to Rule 424(b)(3) (424B3)

Filed Pursuant to Rule 424(b)(3) File Number 333-145989 PROSPECTUS SUPPLEMENT NO. 1, DATED JANUARY 30, 2008 ...

Callisto Pharmaceuticals Inc - Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant...

Callisto Pharmaceuticals Inc - Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT ...

Callisto Pharmaceuticals Inc - Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT ...

Callisto Pharmaceuticals Inc - Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Callisto Pharmaceuticals, (KAL)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

KAL Actualités

Callisto Pharmaceuticals Inc - Current report filing (8-K)

Callisto Pharmaceuticals Inc - Quarterly Report (10-Q)

Callisto Pharmaceuticals Inc - Amended Statement of Ownership (SC 13G/A)

Callisto Pharmaceuticals Inc - Notice of Effectiveness (EFFECT)

Callisto Pharmaceuticals Inc - Securities Registration Statement (simplified form) (S-3)

Callisto Pharmaceuticals Inc - Current report filing (8-K)

Callisto Pharmaceuticals, Inc. Receives Notice of Delisting From Amex - Subject to Appeal -

Callisto Pharmaceuticals Inc - Current report filing (8-K)

Callisto Pharmaceuticals Inc - Annual Report (10-K)

Callisto Pharmaceuticals Inc - Statement of Ownership (SC 13G)

Callisto Pharmaceuticals Inc - Prospectus filed pursuant to Rule 424(b)(3) (424B3)

Callisto Pharmaceuticals Inc - Current report filing (8-K)

Callisto Pharmaceuticals Inc - Current report filing (8-K)

Callisto Pharmaceuticals Inc - Current report filing (8-K)

Callisto Pharmaceuticals Inc - Statement of Changes in Beneficial Ownership (4)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

BLACK FRIDAY

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Callisto Pharmaceuticals, (KAL) Actualités

Callisto Pharmaceuticals, (KAL)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

KAL Actualités

Callisto Pharmaceuticals Inc - Current report filing (8-K)

Callisto Pharmaceuticals Inc - Quarterly Report (10-Q)

Callisto Pharmaceuticals Inc - Amended Statement of Ownership (SC 13G/A)

Callisto Pharmaceuticals Inc - Notice of Effectiveness (EFFECT)

Callisto Pharmaceuticals Inc - Securities Registration Statement (simplified form) (S-3)

Callisto Pharmaceuticals Inc - Current report filing (8-K)

Callisto Pharmaceuticals, Inc. Receives Notice of Delisting From Amex - Subject to Appeal -

Callisto Pharmaceuticals Inc - Current report filing (8-K)

Callisto Pharmaceuticals Inc - Annual Report (10-K)

Callisto Pharmaceuticals Inc - Statement of Ownership (SC 13G)

Callisto Pharmaceuticals Inc - Prospectus filed pursuant to Rule 424(b)(3) (424B3)

Callisto Pharmaceuticals Inc - Current report filing (8-K)

Callisto Pharmaceuticals Inc - Current report filing (8-K)

Callisto Pharmaceuticals Inc - Current report filing (8-K)

Callisto Pharmaceuticals Inc - Statement of Changes in Beneficial Ownership (4)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

BLACK FRIDAY

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres